Business
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D
Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all cohorts, including redosed healthy volunteersStudy results support the chronic dosing of SAB-142 in an outpatient setting for the treatment of stage 3 autoimmune type 1 diabetesPhase 2b SAFEGUARD trial underway and recruiting at multiple sites around the world MIAMI, Dec. 17, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company
About this update from Sab Biotherapeutics, Inc.
[{"type":"image","alt":"SAB Biotherapeutics, Inc.","displaySize":"","headline":null,"caption":"SAB Biotherapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":123,"url":"https://media.zenfs.com/en/globenewswire.com/e5f8996aaa758da6bd63f582a6d0edc0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nx_udecyR0_0bIWMMlxwug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e5f8996aaa758da6bd63f582a6d0edc0","width":300,"height":123}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all cohorts, including redosed healthy volunteers","length":158,"tagName":"p"}]},{"val":[{"type":"text","content":"Study results support the chronic dosing of SAB-142 in an outpatient setting for the treatment of stage 3 autoimmune type 1 diabetes","length":132,"tagName":"p"}]},{"val":[{"type":"text","content":"Phase 2b SAFEGUARD trial underway and recruiting at multiple sites around the world","length":83,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":373,"olType":false},{"type":"text","content":"MIAMI, Dec. 17, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced positive, confirmatory data from a Phase 1 trial of SAB-142 in a single- and multiple-ascending dose among healthy volunteers (n=62), including a re-dosed cohort, and T1D patients (n=6). The study met its primary objectives to establish a safety profile and characterize pharmacodynamic activity enabling SAB-142 to advance to Phase 2b clinical development in the SAFety and Efficacy of human anti-thymocyte immunoGlobUlin SAB-142 ARresting progression of type 1 Diabetes (SAFEGUARD) clinical trial, now underway.","length":786,"tagName":"p"},{"type":"text","content":"In the Phase 1 trial, nine (9) cohorts of healthy volunteers (HVs) and one (1) cohort of T1D patients were dosed with a single 0.03-4.5mg/kg dose or multiple doses of SAB-142.","length":175,"tagName":"p"},{"type":"text","content":"SAB-142 was well-tolerated in both healthy volunteers and T1D patients. SAB-142 demonstrates a s...